{"schema_version":"secwatch.filing_event.v1","accession":"0000105770-25-000007","form_type":"8-K","ticker":"WST","cik":"0000105770","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2025-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.829712+00:00","generated_at":"2026-05-26T21:56:19.780678+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"West Pharma Q4 net sales $748.8M (+2.3%), adj EPS $1.82; FY25 guidance $6.00-$6.20 EPS","bullets":["Q4 organic net sales grew 3.3%, driven by Proprietary Products (+4.5%) led by self-injection devices.","FY 2025 guidance: net sales $2.875B-$2.905B; adjusted EPS $6.00-$6.20 (vs. FY24 $6.75).","Proprietary Products Q4 HVP sales were 74% of segment; Biologics unit had high-single-digit organic growth.","FY 2024 free cash flow $276.4M, down 33.3%; $560.9M spent on share repurchases during year.","CEO cited improving HVP trends in Biologics/Generics and growth from Annex 1 and GLP-1."],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-25-000007","json":"https://secwatch.observer/filing/0000105770-25-000007.json","markdown":"https://secwatch.observer/filing/0000105770-25-000007.md","text":"https://secwatch.observer/filing/0000105770-25-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577025000007/0000105770-25-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577025000007/wst-20250213.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T21:56:19.780678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}